Skip to main
COCH

COCH Stock Forecast & Price Target

COCH Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Envoy Medical is well positioned for success with its differentiated, fully implanted Acclaim CI device, targeting a concentrated market with high-volume sites and potential for cost savings for payors and patients. Being the first-to-market fully implanted cochlear implant could drive strong commercial adoption as Envoy aims to be the leader in the U.S market. With a seasoned CEO at the helm, and potential for future expansion into other markets and product developments, Envoy Medical appears to be a compelling opportunity for long-term investors.

Bears say

Envoy Medical is facing several challenges in the market, including the underutilization of cochlear implants due to low awareness and access, potential competition from major players who are developing their own fully implanted CIs, and reliance on single-source suppliers for critical components. In addition, the company's limited initial rollout and high pricing strategy may place a burden on customers and hinder adoption. Combined with its history of significant operating losses and vulnerability to supply chain disruptions, these factors contribute to a negative outlook for Envoy's stock.

COCH has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Envoy Medical Inc (COCH) Forecast

Analysts have given COCH a Strong Buy based on their latest research and market trends.

According to 1 analysts, COCH has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Envoy Medical Inc (COCH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.